Publications by authors named "Richard D Baird"

Claim this Profile
C
Collaborative framework on responsible AI in LLM-driven CDSS for precision oncology leveraging real-world patient data.
Sonja Mathes, Dyke Ferber, Tobias Dreyer, Kai J Borm, Luise Modersohn, Richard D Baird

NPJ Precis Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2- Advanced Breast Cancer: Results from SERENA-1.
Richard D Baird, Begoña Bermejo de Las Heras, Manuel Ruiz-Borrego, Christos Vaklavas, Irene Moreno

Clin Cancer Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Prognostic and Predictive Impact of Circulating Tumour DNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH Trial.
Iseult M Browne, Javier Pascual, Rosalind J Cutts, Belinda Kingston, Sarah Hrebien, Richard D Baird

Clin Cancer Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using circulating tumor DNA as a novel biomarker of efficacy for dose-finding designs in oncology.
Xijin Chen, Pavel Mozgunov, Richard D Baird, Thomas Jaki

Stat Methods Med Res· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
R C Coombes, Sacha Howell, Simon R Lord, Laura Kenny, Janine Mansi, Richard D Baird

Nat Commun· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adaptive enrichment trial designs using joint modelling of longitudinal and time-to-event data.
Abigail J Burdon, Richard D Baird, Thomas Jaki

Stat Methods Med Res· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment.
Antonino Glaviano, Seth A Wander, Richard D Baird, Kenneth C-H Yap, Hiu Yan Lam

Drug Resist Updat· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer Core Europe: Leveraging Institutional Synergies to Advance Oncology Research and Care Globally.
Javier Carmona, Elena Chavarria, Kate Donoghue, Christina von Gertten, Petra Oberrauch, Richard D Baird

Cancer Discov· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010).
Alistair Ring, Lucy S Kilburn, Alex Pearson, Laura Moretti, Angelica Afshari-Mehr, Richard D Baird

Clin Cancer Res· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
R C Coombes, Sacha Howell, Simon R Lord, Laura Kenny, Janine Mansi, Richard D Baird

Nat Commun· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer.
Antonino Glaviano, Aaron S C Foo, Hiu Y Lam, Kenneth C H Yap, William Jacot, Richard D Baird

Mol Cancer· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
R C Coombes, Sacha Howell, Simon R Lord, Laura Kenny, Janine Mansi, Richard D Baird

Nat Commun· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Prior Trastuzumab and Pertuzumab.
Stefanie Fischer, Thorsten O Götze, Aurelius Omlin, Richard D Baird, Keith M Dawson

JCO Precis Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Road Map for Designing Phase I Clinical Trials of Radiotherapy-Novel Agent Combinations.
Sarah R Brown, Samantha Hinsley, Emma Hall, Chris Hurt, Richard D Baird

Clin Cancer Res· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors.
Atish D Choudhury, Celestia S Higano, Johann S de Bono, Natalie Cook, Dana E Rathkopf, Richard D Baird

Clin Cancer Res· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology.
David Tamborero, Rodrigo Dienstmann, Maan Haj Rachid, Jorrit Boekel, Adria Lopez-Fernandez, Richard D Baird

Nat Cancer· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA.
Irena Hudecova, Christopher G Smith, Robert Hänsel-Hertsch, Chandra S Chilamakuri, James A Morris, Richard D Baird

Genome Res· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology.
David Tamborero, Rodrigo Dienstmann, Maan Haj Rachid, Jorrit Boekel, Adria Lopez-Fernandez, Richard D Baird

Nat Cancer· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Genomic profile of advanced breast cancer in circulating tumor DNA.
Belinda Kingston, Rosalind J Cutts, Hannah Bye, Matthew Beaney, Giselle Walsh-Crestani, Richard D Baird

Nat Commun· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic profile of advanced breast cancer in circulating tumour DNA.
Belinda Kingston, Rosalind J Cutts, Hannah Bye, Matthew Beaney, Giselle Walsh-Crestani, Richard D Baird

Nat Commun· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors.
Richard D Baird, Constanza Linossi, Mark Middleton, Simon Lord, Adrian Harris

J Clin Oncol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.
Nicholas C Turner, Belinda Kingston, Lucy S Kilburn, Sarah Kernaghan, Andrew M Wardley, Richard D Baird

Lancet Oncol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER Breast Cancer.
Susana Ros, Alan J Wright, Paula D'Santos, De-En Hu, Richard L Hesketh, Richard D Baird

Cancer Cell· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.
Peter Schmid, Jacinta Abraham, Stephen Chan, Duncan Wheatley, Adrian Murray Brunt, Richard D Baird

J Clin Oncol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer.
Iain R Macpherson, Pavlina Spiliopoulou, Saeed Rafii, Matilde Saggese, Richard D Baird

Breast Cancer Res· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis